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OBJECTIVES: The objective of this analysis was to examine
whether the Dermatology Life Quality Index (DLQI) provided
any additional information beyond what is captured by the Pso-
riasis Areas and Severity Index (PASI) in psoriasis. METHODS:
The DLQI is used to assess Health-related Quality of Life
(HRQL) in psoriasis, with higher scores corresponding to worse
HRQL. The percent improvement in PASI is the key clinical
measure used to assess treatment effect in psoriasis. We used a
simple mediation model, used in social science to evaluate direct
and indirect effects. This model involves estimating the follow-
ing equations:DDLQI = i1 + A * treatment; DPASI = i2 + B *
treatment; DDLQI = i3 + C * DPASI + D * treatment. If A and
B are not signiﬁcant, mediation is not likely to exist. The indi-
rect effect of treatment on DDLQI (mediated by PASI) is given
by B*C. If D is signiﬁcant, DLQI provides additional informa-
tion beyond what is captured by PASI. We used data from two
large randomized, double-blind clinical trials, comparing inﬂix-
imab to placebo. The change from baseline to week 10 was used
to estimate the equations. RESULTS: A total of 1213 patients
were enrolled in the two trials. The regression estimates were:
DDLQI = -0.51 - 9.6a * treatment; DPASI = 7.52a + 73.98a *
treatment; DDLQI = 0.19 - 0.09a * DPASI - 2.73a * treatment.
The indirect effect was signiﬁcant. However, the direct treatment
effect on DLQI (not mediated by PASI) was also signiﬁcant.
CONCLUSIONS: The DLQI is a useful complement to PASI in
assessing psoriasis treatments, as it captures additional informa-
tion regarding treatment. Mediation analysis can be a useful
method to assess the incremental value of HRQL measures. ap <
0.05.
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POTENTIAL BENEFITS OF SMOKING CESSATION
TREATMENT COVERAGE AT THE WORKPLACE
Halpern MT1, Schmier JK1, Dirani RG2
1Exponent, Alexandria,VA, USA, 2Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To demonstrate the potential beneﬁts of coverage
for pharmacologic smoking cessation treatments at the work-
place by evaluation of a cost of illness model. METHODS: A
cost of illness model utilizing a hypothetical cohort of 1000
employees was used to evaluate the impact of coverage versus
non-coverage of pharmacologic smoking cessation treatments in
the workplace represented by direct beneﬁts to employee health
and indirect beneﬁts to employers (decreased absenteeism and
increased productivity). Data were derived from a previously
published smoking cessation model with future costs and out-
comes discounted at 3% annually. RESULTS: By providing cov-
erage of pharmacologic smoking cessation treatments, the rate
of smoking cessation could increase by 5%, which translates to
almost an additional 100 of 1000 smokers quitting over a 10-
year period. This would have a direct impact on health care costs
due to the avoidance of various smoking-related illnesses, such
as heart disease, cerebrovascular disease, and lung cancer. In the
ﬁrst year following the initiation of coverage, direct savings on
health care costs is projected to be approximately $21,000. After
5 years, the savings increases to $231,000, and over 10 years, a
savings of $610,000 is projected. When indirect cost savings are
considered, the projected economic beneﬁt almost doubles. In the
ﬁrst year, health care cost savings increase to $41,000, and after
5 and 10 years, savings increase to $451,000 and $1.2 million,
respectively. If the rate of smoking cessation increased from 5%
to 10%, health care savings would increase to $41,000 after the
ﬁrst year and $1 million after 10 years. By incorporating indi-
rect cost savings, these numbers increase to $82,000 after the
ﬁrst year and $2 million after 10 years. CONCLUSION: This
cost of illness model demonstrates a potentially important
savings resulting from the provision of pharmacologic smoking
cessation treatment.
SMOKING—Methods and Concepts
PSM2
EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS
Yaffe K
University of Arizona,Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to examine the
extent to which reported quality of life differs between smokers
and nonsmokers when other physical and mental health status
factors are controlled for. METHODS: Data from the 2003
Medical Expenditure Panel Survey was used. This dataset repre-
sents 290,604,436 non-institutionalized adults in the US, 22%
of which were smokers. Three initial logistic regressions were run
using smoking status as the dependent variable. The ﬁrst logis-
tic regression included demographics and education level as
explanatory variables; the second model included diagnosis-
related variables; and the last model considered other health-
related issues such as feeling calm and peaceful, having
functional limitations, etc. Variables signiﬁcantly associated with
smoking in the logistic regressions were used as covariates in a
linear regression with perceived health status as the dependent
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variable. A univariate model estimating the effect of smoking on
health status was also run. RESULTS: After adjusting for demo-
graphics and other health status measures, smoking remained a
highly signiﬁcant factor affecting perceived health status,
although the inﬂuence of smoking decreased by 40%. In the uni-
variate model, the coefﬁcient on smoking was -0.43 (t = -15.23,
p < 0.001). When other explanatory variables were included in
the model, the coefﬁcient on smoking status was -0.26 (t =
-11.00, p < 0.001). In the ﬁnal model, all explanatory variables
showed a signiﬁcant effect on perceived health status, except for
sex. Factors with the highest effect on health status (largest
absolute t-statistics) were pain, any physical limitation, high
blood pressure, and smoking, respectively. CONCLUSIONS:
Although the outcome variable is measured on a ﬁve-point scale,
from 1 (“excellent”) to 5 (“poor”), performing an exploratory
generalized ordered logit model suggested similar associations.
The effect of smoking was consistent throughout the scale of
health status ratings.
SURGERY—Cost Studies
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COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR)
COMPARED TO OPEN SURGICAL REPAIR (OSR) OF
ABDOMINAL AORTIC ANEURYSMS (AAA)
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Blackhouse G1, O’Reilly D1,Tarride JE1
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AAA is a prevalent health condition affecting up to 14% of males
and 6% of females. Untreated AAAs is a serious health concern
due to signiﬁcant risks of rupture and death. OBJECTIVES: Esti-
mate the cost-utility of elective EVAR compared to OSR for
treating non-ruptured AAAs. METHODS: A decision analytic
model was constructed to represent the long term cost-
effectiveness of AAA. A systematic review of the literature was
conducted for estimates of key model parameters (including tech-
nical and clinical success rates, complication rates, conversion
rates and mortality). The review of the literature was supple-
mented with a prospective follow-up of patients from a large ter-
tiary hospital for information on costs and health-related quality
of life. Cost-utility was assessed over a one-year period. Deter-
ministic sensitivity analyses were used to assess the impact of
methodological and modeling uncertainty and probabilistic sen-
sitivity analyses was used for parameter uncertainty. RESULTS:
The 59 comparative studies identiﬁed from the literature suggest
the technical and clinical success rates are lower for EVAR
patients, however, EVAR treated patients tended to be older,
male, and had larger aneurysms, increased surgical risk, and
more comorbidities than OSR trial patients. Our prospective
study showed success rates for both OSR and EVAR are very
high and complication rates are much lower than reported in the
published literature. Cost-utility based on success and complica-
tion rates from the literature suggests EVAR cost $160,176 per
QALY compared to OSR. However, results from our prospective
study suggest EVAR costs only $59,485 per QALY in all AAA
patients and may even dominate OSR in high surgical risk
patients. CONCLUSIONS: Using results from literature reviews
of non-randomized trials for input into an economic model can
be misleading. The predominance of non-randomized trials com-
paring EVAR and OSR highlights the importance of adjusting
for baseline imbalances in patient risk.
SURGERY—Patient Reported Outcomes
PSU2
THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL
INTERVENTIONS IN THE UK
Wechowski JG1, Poole CD1, Currie CJ2
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OBJECTIVE: To examine the relationship between costs of
surgery in relation to changes in health status. METHODS: The
responses of 10,000 patients to a routine post-discharge survey
were evaluated (Health Outcomes Data Repository [HODaR]).
Respondents were asked to rate their health both prior to admis-
sion and on the day of survey completion (>40 days post-
discharge) on a scale of 1 (worst possible health) to 100 (best
possible health). Admissions were classiﬁed as either elective or
emergency procedures. The primary surgical procedure was clas-
siﬁed using 3-character OPCS4 codes. The cost for each admis-
sion was calculated using the NHS HRG grouping algorithm.
RESULTS: “Before” and “after” data were available for 6456
elective admissions and 1387 emergency admissions who had all
undergone a surgical procedure. Mean self-reported difference in
health status was 4.8 units (SD 20.7). There was no difference
in health change between elective or emergency admissions (p >
0.05). For elective procedures with 25 cases or more (n = 45 
procedures) a logarithmic relationship between cost and mean
health change was evident (DQoL = 6.3024 ¥ Lncost - 36.62; r2
= 0.57), and a linear function best described the same relation-
ship for emergency procedures (DQoL = 0.0022 ¥ cost + 1.4814;
r2 = 0.50). Procedures involving a notably improved cost effec-
tiveness ratio included tonsilectomy, cholecystectomy and
primary excision of lumbar inter-vertebral disc. The mean cost
effectiveness ratio for elective procedures was ≤250 per DQoL
unit and ≤440 per unit for emergency surgery. CONCLUSIONS:
At a macro level there was a distinct association between ﬁnan-
cial cost and short term outcome for operative procedures. The
mean cost effectiveness ratio for individual procedures showed
a linear association for emergency surgery and a logarithmic
association for elective surgery. Procedures which reduce pain
appear to be the most cost-effective where DQoL is the outcome.
